Estreptoquinasa

Base Information

• Chemical Name: Estreptoquinasa
• CAS No.: 9002-01-1
• Molecular Formula: Unspecified
• Molecular Weight: 197.27400
• Hs Code.: 3504009000
• European Community (EC) Number: 232-647-1
• DSSTox Substance ID: DTXSID00864144
• Mol file: 9002-01-1.mol

Synonyms:Avelizin;Awelysin;Celiase;Distreptase;Kabikinase;Kabivitrum;Streptase;Streptodecase;Streptokinase

Chemical Property of Estreptoquinasa

Chemical Property:

• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.517
• Boiling Point: 343.9oC at 760mmHg
• Flash Point: 161.8oC
• PSA: 49.33000
• Density: 1.113g/cm3
• LogP: 1.95820
• Storage Temp.: −20°C
• XLogP3: 0.3
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 2
• Exact Mass: 197.141578849
• Heavy Atom Count: 14
• Complexity: 211

Purity/Quality:

99.0% Min., ^*data from raw suppliers

Streptokinase ^*data from reagent suppliers

Safty Information:

• Pictogram(s): B,Xi
• Hazard Codes: B,Xi
• Statements: 36/37/38
• Safety Statements: 22-24/25-36-26

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: C1CCC(CC1)C2CC(NC2)C(=O)O
• Description: Streptokinase is a protein produced by certain strains of hemolytic group C streptococcus, and it was the first clinically useful fibrinolytic. Unlike other plasminogen activators, streptokinase is not an enzyme and cannot break any bonds in a plasminogen molecule by itself. It forms an equimolecular compound with plasminogen, thus forming a streptokinase–plasminogen complex. In the plasminogenic region of the resulting complex, certain conformational changes lead to a break in a few peptide bonds, and transformation of this complex into a streptokinase–plasmin complex, or free plasmin, which also decomposes fibrin.
• Uses: This drug has a half-life in the plasma of 15–30 min, and is used intravenously to treat patients with severe, massive pulmonary embolism and thrombus of the veins; it is also used during myocardial infarctions. Recently, a number of streptokinase derivatives have been proposed, in particular acetylated derivatives, which are developed for use as fibrinolytics. Streptokinase is commonly used as a thrombolytic agent in the therapy of ischemic stroke. This therapy carries the important risk of intracerebral hemorrhage. Streptokinase is also used in the treatment of complicated parapneumonic effusions and empyema where adverse reactions, allergic type, are rare. Streptokinase has been used in a study to compare primary coronary intervention and thrombolytic therapy in myocardial infarction patients.
• Therapeutic Function: Enzyme
• Clinical Use: Fibrinolytic: Thrombolysis in DVT, PE, acute arterial thromboembolism, acute MI, thrombosed A-V shunts
• Drug interactions: Potentially hazardous interactions with other drugs Anticoagulants should not be given with streptokinase. Heparin infusions should be stopped 4 hours before streptokinase infusion. If this is not possible, protamine sulphate should be used to neutralise the heparin; heparin infusions can be restarted 4 hours post streptokinase infusion followed by oral anticoagulants.